Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Immunotherapy plus chemotherapy improves outcomes in stage III dMMR colon cancer

A new study from researchers at the Alliance for Clinical Trials in Oncology (Alliance) shows that patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR) had significantly better outcomes when the immunotherapy drug atezolizumab (Tecentriq®) was added to standard chemotherapy after surgery.

25 Mar 2026

Breast cancer patients may avoid lymphedema with radiotherapy approach

Patients with breast cancer may be able to avoid lymphedema, which can occur after surgery to remove lymph nodes in the armpit (the axilla), by having radiotherapy instead.

25 Mar 2026

Breast cancer cells exploit the lung's repair system to support tumor growth

Researchers at the CU Anschutz Cancer Center have discovered how breast cancer cells that spread to the lungs may take advantage of the body's natural healing response and how a commonly used drug might slow that process.

25 Mar 2026

Early blood test could guide personalized lymphoma treatment decisions

Many people with an aggressive blood cancer called diffuse large B cell lymphoma are cured by the current gold standard of treatment: an antibody designed to wipe out cancerous B cells plus a combination of four chemotherapy drugs.

25 Mar 2026

Immune cells use neurotransmitters to regulate health and disease

The article, titled "Emerging roles of immune cell-derived neurotransmitters in immunity and disease," published on March 17, 2026, in Immunity & Inflammation, provides a timely and authoritative review of how innate and adaptive immune cells-including macrophages, dendritic cells, natural killer cells, T cells, and B cells-produce and respond to classic neurotransmitters.

25 Mar 2026

Detailed cell atlas reveals earliest changes in prostate cancer

Prostate cancer affects one in five Australian men, making it the most common cancer in the country.

25 Mar 2026

Systematic review identifies stress-induced biological triggers in oncology

Stress is a constant companion in the oncologist's office. It appears at the time of diagnosis, increases with each stage of treatment, and often does not resolve even after therapy formally ends. It accompanies therapeutic decisions, waiting for test results, fear of recurrence, and changes in daily functioning. Studies show that chronic stress can trigger biological processes that promote disease progression and weaken the body's defenses.

25 Mar 2026

iXCells Biotechnologies joins international collaboration to evaluate chemotherapeutic toxicity in human organoids

iXCells Biotechnologies ("iXCells"), a leading provider of human cell-based solutions and custom iPSC services, today announced it has entered an international collaboration with Rosebud Biosciences ("Rosebud"), Kantify, and Incite to evaluate off-target chemotherapeutic toxicities in patient-specific organoids.

From iXCells Biotechnologies 25 Mar 2026

Online tool helps cancer patients share genetic risk with families

When a person with cancer finds out they carry an inherited genetic variant that puts them at higher risk of cancer, the results can help inform their treatment or steps to prevent additional cancer.

24 Mar 2026

Personalized radiotherapy reduces the risk of breast cancer recurrence

The chances of breast cancer recurring remain very low when patients are treated with radiotherapy that is tailored to their individual risk following chemotherapy and surgery. These are the findings of a ten-year study presented at the 15th European Breast Cancer Conference (EBCC15) in Barcelona today (Wednesday).

24 Mar 2026

Polyurethane-coated implants may reduce scarring after breast reconstruction surgery

Women who are treated with mastectomy for breast cancer often choose to have surgery to reconstruct the breast using an implant.

24 Mar 2026

CREB5 drives stem cell-like transcriptional programs in aggressive prostate cancer

A new research paper was published in Volume 17 of Oncotarget on March 17, 2026, titled "CREB5 regulates stem cell-like transcriptional programs to enhance tumor progression in prostate cancer."

24 Mar 2026

Insilico and ASKA partner to advance AI-driven gynecological drug discovery

Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), today announced a strategic research collaboration with ASKA Pharmaceutical Co., Ltd. ("ASKA"), a specialized pharmaceutical company with a strong focus on internal medicine, obstetrics, and gynecology.

24 Mar 2026

Webinar introduces advanced bioinformatics tool to interpret mutations in cancer genomes

A free open-access webinar will introduce the Cancer Genome Interpreter (CGI), an advanced bioinformatics tool to interpret mutations in cancer genomes developed by IRB Barcelona and co-created with European hospitals to turn complex cancer genomics into actionable insights.

23 Mar 2026

Blood-based test helps personalize breast cancer care for older patients

For women age 70 and over with a common form of breast cancer, determining "the right size" of treatment can be challenging, in part because clinicians have limited tools to guide individualized treatment decisions.

19 Mar 2026

New pathway explains poor response to bladder cancer immunotherapy

Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a biological pathway that helps explain why some bladder cancers do not respond well to immunotherapy.

18 Mar 2026

Combination therapy shows promise for leptomeningeal metastasis in breast cancer

Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.

18 Mar 2026

Aptamer Group launches targeted radiopharmaceutical program

Aptamer Group plc, the developer of next‑generation synthetic binders for the life sciences industry, today announced the launch of a new targeted radiopharmaceutical program in collaboration with Radiopharmium Ltd, a UK-based specialist consultancy in radiopharmaceutical development.

From Aptamer Group 18 Mar 2026

Why are men missing cancer tests despite higher positive rates?

A study highlights a gap in cancer prevention, showing men undergo genetic testing less often yet are more likely to carry high-risk cancer variants.

18 Mar 2026

Study: Women survive cancer more but face higher treatment toxicity

Women are more likely to survive cancer than men but face a higher risk of serious and adverse side effects from treatment, according to a landmark international study from Adelaide University.

17 Mar 2026